In the following study, we explored the efficacy of the oral SERD, elacestrant16, in vitro and in PDX models of endocrine-sensitive and endocrine-resistant ER + BC expressing various naturally occurring ESR1 mutations. The gene discussed is ESR1; the disease is breast cancer.